

Cancer
Chemotherapy
Cancer: Chemotherapy (Adult)

B15/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
CHEM01a	30-day mortality figures for palliative intent	Of those in the denominator, the number who have died within 30-days of receiving palliative SACT	Total number of patients who have received SACT in the reporting period	Quarter	Quarterly	SACT	SACT		The following supportive treatments are excluded: . Hormone analogues e.g. progesterones, oestrogens, and somatostatins; . Prophylactic therapies e.g. bisphosphonates (such as pamidronate and zoledronic acid), and denosumab; . Chemoprotectants e.g. vitamins, anti-histamines, and anti-emetics; . Steroids if used alone; . And any other non-cancer treatments e.g. cytoreductive therapies (such as hydroxycarbamide) and growth factors (such as GCSF).	Jan-22 - Mar-22	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22
CHEM01b	30-day mortality figures for curative intent	Of those in the denominator, the number who have died within 30-days of receiving curative SACT	Total number of patients who have received SACT in the reporting period by cancer group	Quarter	Quarterly	SACT	SACT		The following supportive treatments are excluded: . Hormone analogues e.g. progesterones, oestrogens, and somatostatins; . Prophylactic therapies e.g. bisphosphonates (such as pamidronate and zoledronic acid), and denosumab; . Chemoprotectants e.g. vitamins, anti-histamines, and anti-emetics; . Steroids if used alone; . And any other non-cancer treatments e.g. cytoreductive therapies (such as hydroxycarbamide) and growth factors (such as GCSF).	Jan-22 - Mar-22	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22
CHEM02	Proportion of intravenous chemotherapy administrations which result in incident form for all degrees of SACT extravasation	Of those in the denominator, the number of administrations that resulted in an incident form for all degrees of SACT extravasation	The total number of intravenous chemotherapy administrations carried out in the reporting period	Quarter	Quarterly	Provider	SACT		Includes: all cancers the following supportive treatments are excluded: . Hormone analogues e.g. progesterones, oestrogens, and somatostatins; . Prophylactic therapies e.g. bisphosphonates (such as pamidronate and zoledronic acid), and denosumab; . Chemoprotectants e.g. vitamins, anti-histamines, and anti-emetics; . Steroids if used alone; . And any other non-cancer treatments e.g. cytoreductive therapies (such as hydroxycarbamide) and growth factors (such as GCSF).	Jan-22 - Mar-22	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22

Cancer
Chemotherapy
Cancer: Chemotherapy (Adult)

B15/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
CHEM03	Proportion of all patients starting SACT who have been entered into a clinical trial or a study addressing a systemic therapy-related treatment policy	Of those in the denominator, the number of patients who have been entered onto a clinical trial or study addressing a systemic therapy-related treatment policy	The total number of patients starting SACT in the reporting period	Quarter	Quarterly	Provider	Provider		Include all cancers	Jan-22 - Mar-22	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22
CHEM04	Unplanned emergency admissions (AOS) within 30 days of SACT	Of those in the denominator, the number who have had an unplanned emergency admission within 30-days of receiving SACT	Total number of patients who have received SACT in the reporting period	Quarter	Quarterly	SACT	SACT		Includes: all cancers the following supportive treatments are excluded: . Hormone analogues e.g. progesterones, oestrogens, and somatostatins; . Prophylactic therapies e.g. bisphosphonates (such as pamidronate and zoledronic acid), and denosumab; . Chemoprotectants e.g. vitamins, anti-histamines, and anti-emetics; . Steroids if used alone; . And any other non-cancer treatments e.g. cytoreductive therapies (such as hydroxycarbamide) and growth factors (such as GCSF).	Jan-22 - Mar-22	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22
CHEM05	Proportion of patients with suspected neutropenic sepsis who are given antibiotics within 60 minutes of sepsis being identified	Of those in the denominator, the number of patients who were given antibiotics within 60 minutes of sepsis being identified	The total number of patients with suspected neutropenic sepsis in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-21 - Mar-22